As the accuracy of traditional cancer screening is called into question, molecular and genetic tests promise an alternative, noninvasive form of early detection.
While working to understand not only his own rare disease but also how the broader healthcare industry develops treatments for rare diseases as a whole, Onno Faber uncovered the building blocks of his new company.
In his latest book, clinical geneticist and biotech entrepreneur Dr. Phil Reilly chronicles centuries of medical progress that have contributed to recent breakthroughs in rare disease medicines, diagnostics, and clinical care. He says we're just...
New studies demonstrate that treating cancer based on its molecular vulnerabilities, rather than where it originated, could translate to better outcomes for patients
With a new genome sequence, more diverse data sets, and population-specific projects, scientists are making progress in representing humanity’s real DNA diversity.
CAR T therapies juice the immune system. In cancer, they have cured patients who had little hope for survival. Now scientists are asking "What else can they do?"
NFTs have entered a new stage of their life cycle—and the possibilities are endless for this next generation, aptly called Living NFTs.